Xcelerate, Inc. Expands IP with Acquisition of Patent Portfolio
Xcelerate, Inc. (OTC PINK:XCRT) announced the acquisition of a patent portfolio from HS Pharmaceuticals LLC, enhancing its focus on dermatological products for chronic wounds and infections. The deal includes four issued and one pending U.S. patents, as well as two issued and one pending European patent, totaling millions in developmental costs. The acquisition involves issuing 10 million shares of restricted common stock and establishing a profit-sharing arrangement. This move aims to strengthen Xcelerate's technology base and aligns with its strategy to acquire cutting-edge medical innovations.
- Acquisition of a valuable patent portfolio, enhancing XCRT's technology base.
- Partnership with renowned scientists and institutions, potentially leading to innovative product development.
- Profit-sharing arrangement could provide future revenue streams.
- Issuance of 10 million shares may dilute current shareholders' equity.
- Revenues from patents are uncertain and depend on future development and commercialization.
MAULDIN, SC / ACCESSWIRE / May 4, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) today announced that it signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a manufacturer and distributer of dermatological products for chronic wounds, burns and drug resistant infections.
"As many of our shareholders know, this acquisition is the culmination of discussions started nearly two years ago with HS Pharmaceuticals and greatly enhances XCRT's mission of acquiring innovation at the engineering/patent level and developing it for commercialization," said Xcelerate CEO Michael O'Shea. "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world renowned scientists and universities and we are excited to take this amazing intellectual property to the next level."
The portfolio consists of four issued and one pending U.S. patents, two issued and one pending European patent, as well as certain licensing agreements in conjunction with research developed by Cambridge University.
U.S. Patents
- U.S. 9,889,151: methods of treating specific cancers with a composition releasing orthosilicic acid in vivo
- U.S. 9,333,224: methods of treating bacterial infection with a composition releasing orthosilicic acid in vivo
- U.S. 10,493,097: methods of treating specific types of ulcers (wounds) with a composition releasing orthosilicic acid in vivo
- U.S. 16/089,613: composition for bone repair/replacement comprising silicate and bone/bone surrogate
- U.S. 16/670,060 pending
European Patents - Validated in Germany, Spain, France, the United Kingdom, Ireland, Italy
- EP 2211868: Silicate solution for treating melanoma
- EP 3305305: Silicate solution for wound healing
- EP 21178277.6 pending
- In-licensed IP (United Kingdom Research and Innovation)
- Granted U.S., EP, AU, JP, Eurasian, CN patents
- Pending in CA, HK, KR, SG
The acquisition of this new patent portfolio represents the culmination of years of research by world renowned scientists and institutions as well as millions of dollars in development costs and further enhances the Company's existing patent and technology base. Xcelerate has issued 10 million shares of its' restricted common stock to HS Pharmaceuticals for these assets. The relevant agreement also provides for a profit-sharing arrangement based on future earnings of the assets as well as providing a Board seat for one of HS Pharmaceuticals members.
About Xcelerate, Inc.
Xcelerate is a start-up, development stage company that has assembled an Advisory Board of internationally renowned translational clinicians and engineers to assist the Company in identifying and acquiring cutting-edge engineering technological advancements and intellectual property, most of which does not have immediately obvious applications to medical technology and clinical care. The Company goal is to acquire innovation at the engineering/patent level and develop med tech and clinical care applications.
Xcelerate has also recently acquired a
For more information, visit the company's website at http://Xcelerate.Global/
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
Xcelerate Contact
SOURCE: Xcelerate, Inc.
View source version on accesswire.com:
https://www.accesswire.com/700001/Xcelerate-Inc-Expands-IP-with-Acquisition-of-Patent-Portfolio
FAQ
What does the acquisition of the patent portfolio by Xcelerate, Inc. entail?
How many shares did Xcelerate, Inc. issue for the acquisition of the patents?
What are the strategic benefits of Xcelerate's acquisition of HS Pharmaceuticals' patents?
When was the acquisition of HS Pharmaceuticals' patents announced?
What are the future implications of the acquisition for Xcelerate, Inc.?
